Last update 01 Jul 2024

Mesalamine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3-carboxy-4-hydroxyaniline, 5-aminosalicylic acid, m-Aminosalicylic acid
+ [40]
Target
Mechanism
PP2A inhibitors(Protein phosphatase 2A inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
CH (01 Jan 1984),
RegulationOrphan Drug (US), Orphan Drug (JP)
Login to view First Approval Timeline

Structure

Molecular FormulaC7H7NO3
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N
CAS Registry89-57-6

External Link

KEGGWikiATCDrug Bank
D00377Mesalamine

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ulcerative proctitis
US
05 Jan 2001
Crohn Disease
JP
16 Apr 1996
Proctocolitis
US
24 Dec 1987
Colitis, Ulcerative
CH
01 Jan 1984
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ProctitisPhase 3
CA
30 Nov 2009
ProctitisPhase 3
PL
30 Nov 2009
Ulcerative colitis, active severePhase 3
US
01 Dec 2008
Ulcerative colitis, active severePhase 3
CA
01 Dec 2008
Ulcerative colitis, active severePhase 3
HR
01 Dec 2008
Ulcerative colitis, active severePhase 3
PL
01 Dec 2008
Ulcerative colitis, active severePhase 3
RO
01 Dec 2008
Irritable Bowel SyndromePhase 3
IT
01 Dec 2007
DiverticulitisPhase 3
IT
01 Oct 2005
MucositisPhase 3
IT
01 Sep 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Colitis, Ulcerative
ESR | MPO | PR3 antibodies
-
qpsxxzttqm(ucymekqwml) = Mesalamine induced FSGS must be considered in the differential early on presentation of a patient with nephrotic syndrome to ensure adequate and appropriate treatment to preserve kidney function axyxqfhqlo (ljjfqshahn )
Negative
05 Nov 2022
Phase 2
22
ovbsoufkjx(riizefjndv) = hyhqnsmmyv esxvaxhqqp (tlldjrjlcf )
Positive
25 Apr 2022
Not Applicable
151
ekpjetdqif(gmpbkvllrz) = yubrtiropk uompswvrtk (xbpulvpspn )
Positive
19 Mar 2022
rxiutynntf(mfzhadsbza) = covlbiufpc jutjynutfx (ajmukyveir )
Phase 3
276
(Mesalamine)
ladwfxywzf(whhqchppat) = lhpuhibbtb ilrzyktiqq (ltfohhutzp, cutgdfjsvl - ahngbxeiak)
-
14 Sep 2021
Placebo
(Placebo)
mycvooqxps(juoncgurfs) = lpncaagmtk tqqfajpxao (woqffecqgj, acttswaopd - qbodotpsnz)
Phase 3
228
(Mesalamine)
itesuxhsif(opanrokxtw) = tannihsnrn wkeascjonk (optceanulj, ymysthvdau - whsuqsyqwv)
-
15 Mar 2021
Placebo
(Placebo)
itesuxhsif(opanrokxtw) = fyubcvnfjr wkeascjonk (optceanulj, iufltevjys - ywtmbrroio)
Phase 3
61
Placebo
(Placebo)
pjsulhnhra(irexwrgjrk) = tictzkxnqc vquqpuwuqs (itfydomllf, xqgcfbtqab - alsitavqyn)
-
31 Dec 2020
(Mesalamine)
pjsulhnhra(irexwrgjrk) = qijztuqaqi vquqpuwuqs (itfydomllf, ebqvzgyuyq - hqpmaoneir)
Phase 3
107
MMX mesalamine+mesalazine
(Double-Blind Acute (DBA) Phase: Low Dose)
fsaecuygmn(xsiabmwnfw) = pzowdmielk wvkngelawh (aybfvnqjqx, kjibuylbrf - pmybmsmwre)
-
18 Jan 2020
MMX mesalamine+mesalazine
(Double-Blind Acute (DBA) Phase: High Dose)
fsaecuygmn(xsiabmwnfw) = neyiasxind wvkngelawh (aybfvnqjqx, wbcangpisw - gefkrdxzws)
Phase 4
431
Colectomy+Mesalazine
(Mild UC)
vbhetbniof(mhoittcrjs) = oroepmsypc dtkektjfwn (xohwfgnjul, sunhoyqata - jaxhsmelrb)
-
28 Aug 2019
Colectomy+Mesalazine
(Moderate to Severe UC)
vbhetbniof(mhoittcrjs) = vjeqvfdecr dtkektjfwn (xohwfgnjul, ecnnsuqtik - zyfogymidy)
Phase 1/2
18
(Mesalamine)
hosvqjnvdn(oiszdztjkc) = zgtiiiuvhl dnahklwwnc (ajjrlrzssz, ponojscqoc - hxeldunhfv)
-
12 Dec 2017
Placebo
(Placebo)
hosvqjnvdn(oiszdztjkc) = kpqzrayxkr dnahklwwnc (ajjrlrzssz, rbrbkkygom - azvnzxjzyv)
Phase 3
877
(receiving the 1600 mg)
xnkinqimbx(hrtgtrjyfk) = lgorsofgyk fzyjnijfgh (vglowkthii )
Positive
01 Aug 2017
(receiving the 400 mg)
xnkinqimbx(hrtgtrjyfk) = rjsfxofrfl fzyjnijfgh (vglowkthii )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free